Technical Analysis for NRIX - Nurix Therapeutics, Inc.

Grade Last Price % Change Price Change
D 12.10 -2.89% -0.36
NRIX closed down 2.89 percent on Thursday, January 26, 2023, on 56 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Earnings Movers Other 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish -2.89%
NR7 Range Contraction -2.89%
Upper Bollinger Band Walk Strength -2.89%
Earnings Movers Other -2.89%
Wide Bands Range Expansion -2.89%
Overbought Stochastic Strength -2.89%
Gapped Down Weakness -2.89%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 8 hours ago
50 DMA Support about 11 hours ago
Fell Below 50 DMA about 11 hours ago
Down 3% about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Nurix Therapeutics, Inc. Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Tyrosine Kinase Immune Disorders Small Molecule Therapies Gilead Sciences Oncogene Bruton's Tyrosine Kinase

Is NRIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.2
52 Week Low 7.52
Average Volume 314,445
200-Day Moving Average 12.94
50-Day Moving Average 11.89
20-Day Moving Average 11.51
10-Day Moving Average 12.24
Average True Range 0.75
RSI 53.49
ADX 18.93
+DI 20.80
-DI 18.49
Chandelier Exit (Long, 3 ATRs) 10.94
Chandelier Exit (Short, 3 ATRs) 11.91
Upper Bollinger Bands 13.15
Lower Bollinger Band 9.87
Percent B (%b) 0.68
BandWidth 28.46
MACD Line 0.26
MACD Signal Line 0.10
MACD Histogram 0.1573
Fundamentals Value
Market Cap 470.15 Million
Num Shares 38.9 Million
EPS -1.82
Price-to-Earnings (P/E) Ratio -6.63
Price-to-Sales 113.01
Price-to-Book 4.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.32
Resistance 3 (R3) 13.34 12.97 13.11
Resistance 2 (R2) 12.97 12.66 12.95 13.04
Resistance 1 (R1) 12.53 12.47 12.35 12.51 12.98
Pivot Point 12.16 12.16 12.06 12.14 12.16
Support 1 (S1) 11.72 11.85 11.54 11.70 11.22
Support 2 (S2) 11.35 11.66 11.33 11.16
Support 3 (S3) 10.91 11.35 11.09
Support 4 (S4) 10.89